Skip to main content

Table 1 Demographic and clinical characteristics for the pooled ADC and PredictND cohort (n = 883) according to diagnosis

From: Computerized decision support to optimally funnel patients through the diagnostic pathway for dementia

 

N

CN n = 188

MCI n = 191

ADD n = 302

FTD n = 107

VaD n = 35

DLB n = 60

Demographics

 Age, years

883

61 ± 8

66 ± 8

67 ± 78

63 ± 7

70 ± 8

69 ± 8

 Sex, female

883

80 (42.6)

70 (36.6)

163 (54.0)

46 (43.0)

11 (31.4)

8 (13.3)

 Education, years

836

13 [10-17]

12 [9-14]

10 [9-13]

10 [9-13]

10 [9-13]

10 [9-13]

Digital cognitive screening, cCOG

 cCOG, learning

111

23 ± 8

19 ± 4

15 ± 5

17 ± 6

19 ± NA

15 ± 8

 cCOG, recall

110

9 ± 2

6 ± 2

4 ± 2

7 ± 5

8 ± NA

6 ± 3

 cCOG, TMT-a (s)

110

48 ± 16

65 ± 22

77 ± 32

163 ± 173

63 ± NA

84 ± 35

 cCOG, TMT-b (s)

104

171 ± 98

231 ± 82

322 ± 153

153 ± NA

283 ± NA

246 ± 91

Neuropsychology

 MMSE [0–30]

879

29 [28-30]

27 [25-29]

23 [19-25]

25 [23-27]

26 [23-27]

24 [22-26]

 Memory, learning

839

42 ± 9

31 ± 8

22 ± 8

28 ± 8

24 ± 8

25 ± 9

 Memory, recall

839

9 ± 3

4 ± 3

2 ± 2

4 ± 3

3 ± 3

4 ± 3

 TMT-A (s)

861

36 ± 14

48 ± 19

72 ± 39

59 ± 30

90 ± 37

92 ± 38

 TMT-B (s)

710

85 ± 36

133 ± 67

191 ± 82

161 ± 77

224 ± 82

218 ± 87

 Animal fluency

855

23 ± 6

19 ± 5

13 ± 6

12 ± 7

11 ± 5

13 ± 6

Neuropsychiatric symptoms

 GDS [0–15]

783

3 ± 3

3 ± 3

3 ± 2.3

3 ± 3

4 ± 3

4 ± 3

 NPI, total score

706

8 ± 10

10 ± 11

11 ± 10

21 ± 17

14 ± 9

14 ± 12

Functional assessment

 DAD [0–100]

510

100 [92–100]

93 [86–98]

88 [75–96]

83 [63–97]

70 [66–83]

77 [60–96]

Automated MRI biomarkers

 cMTA, left

883

0.35 ± 0.61

0.94 ± 1.00

1.53 ± 0.92

2.07 ± 1.33

1.79 ± 1.24

1.08 ± 0.75

 cMTA, right

883

0.37 ± 0.58

0.96 ± 0.99

1.48 ± 0.93

1.72 ± 1.27

1.73 ± 1.10

1.07 ± 0.85

 cGCA

882

0.51 ± 0.58

0.80 ± 0.71

1.30 ± 0.74

1.37 ± 0.68

1.70 ± 0.68

1.19 ± 0.59

 cFazekas

881

0.65 ± 0.66

1.15 ± 0.93

1.06 ± 0.80

0.90 ± 0.81

2.64 ± 0.53

1.01 ± 0.75

 WMH, volume

881

3.71 ± 6.23

10.58 ± 18.83

8.29 ± 11.85

6.36 ± 11.40

50.54 ± 31.58

6.08 ± 6.99

 Anterior–posterior score

883

0.35 ± 1.21

0.01 ± 1.29

0.30 ± 1.68

-2.68 ± 2.39

0.28 ± 1.52

0.42 ± 1.37

 AD similarity

882

0.39 ± 0.10

0.47 ± 0.12

0.60 ± 0.11

0.44 ± 0.12

0.60 ± 0.10

0.51 ± 0.10

Cerebrospinal fluid

 Aβ42, pg/ml

883

1034 ± 246

830 ± 297

617 ± 164

1017 ± 266

798 ± 215

845 ± 249

 Total tau, pg/ml

883

284 ± 152

446 ± 274

717 ± 413

383 ± 205

302 ± 163

311 ± 158

 p-tau, pg/ml

883

48 ± 18

65 ± 32

86 ± 38

49 ± 22

42 ± 20

47 ± 21

  1. Data presented in mean ± SD, median [IQR], or n(%)
  2. Abbreviations: CN cognitively normal, MCI mild cognitive impairment, ADD Alzheimer’s disease dementia, FTD frontotemporal dementia, VaD vascular dementia, DLB dementia with Lewy bodies, MMSE Mini-Mental state Examination, cCOG computerized cognitive test, TMT Trail Making Test, GDS geriatric depression scale, NPI neuropsychiatric inventory, DAD disability assessment for dementia, cMTA computed medial temporal lobe atrophy, cGCA computed global cortical atrophy, WMH white matter hyperintensities, Aβ42 β-amyloid 1–42, p-tau phosphorylated tau
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193